Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

The Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Never Used Anti-HIV Drugs

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov Identifier:
NCT00001067
First received: November 2, 1999
Last updated: May 1, 2012
Last verified: May 2012

November 2, 1999
May 1, 2012
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00001067 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
The Effectiveness of Three Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Never Used Anti-HIV Drugs
A Phase II Randomized Study of the Virologic and Immunologic Effects of Zidovudine Plus Lamivudine (3TC) Versus d4T Versus Zidovudine Plus d4T in HIV-Infected Patients With CD4 Cell Counts Between 300-600/mm3 and No Previous Nucleoside Experience

To determine drug efficacy and safety in HIV-infected patients treated with zidovudine ( AZT ) versus stavudine ( d4T ) versus both drugs. Also, to compare short- and long-term changes in magnitude of HIV RNA over time.

Asymptomatic patients with CD4 counts over 300 cells/mm3 are more likely to tolerate any of the nucleoside analogs. d4T, with a favorable toxicity profile and demonstrated anti-HIV activity in previous studies, provides an additional therapeutic option.

Asymptomatic patients with CD4 counts over 300 cells/mm3 are more likely to tolerate any of the nucleoside analogs. d4T, with a favorable toxicity profile and demonstrated anti-HIV activity in previous studies, provides an additional therapeutic option.

Patients are randomized to receive d4T alone, AZT alone, or both in combination for at least 12 weeks. After week 12, 3TC is added to the combination arm. Treatment continues for up to 48 weeks (was a total of 48 weeks, amended 3/26/96).

Interventional
Phase 2
Primary Purpose: Treatment
HIV Infections
  • Drug: Lamivudine
  • Drug: Stavudine
  • Drug: Zidovudine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
105
November 1997
Not Provided

Inclusion Criteria

Concurrent Medication:

Required:

  • TMP / SMX, aerosolized pentamidine, or dapsone for PCP prophylaxis.

Allowed:

  • Atovaquone.
  • IV pentamidine.
  • TMP / SMX.
  • Trimetrexate.
  • Trimethoprim-dapsone.
  • Clindamycin-primaquine.
  • Topical antifungals.
  • Clotrimazole.
  • Ketoconazole.
  • Fluconazole.
  • Amphotericin B.
  • Itraconazole.
  • Rifabutin.
  • Isoniazid.
  • Pyrazinamide.
  • Clofazimine.
  • Clarithromycin.
  • Azithromycin.
  • Ethambutol.
  • Amikacin.
  • Ciprofloxacin.
  • Ofloxacin.
  • Pyrimethamine.
  • Sulfadiazine.
  • Clindamycin.
  • Filgrastim ( G-CSF ).
  • Up to 1000 mg/day acyclovir.
  • Erythropoietin.
  • Antibiotics.
  • Antipyretics.
  • Analgesics.
  • Antiemetics.
  • Rifampin.

Concurrent Treatment:

Allowed:

  • Local radiation therapy.

Patients must have:

  • HIV infection.
  • CD4 count 300 - 600 cells/mm3.
  • NO history of AIDS.
  • NO active opportunistic infection.
  • NO prior nucleoside therapy.
  • Life expectancy at least 2 years.

Exclusion Criteria

Co-existing Condition:

Patients with the following symptoms or conditions are excluded:

  • Serious underlying medical condition other than HIV such that life expectancy is less than 2 years.
  • Malignancy requiring systemic cytotoxic chemotherapy.
  • Active grade 2 or worse peripheral neuropathy.

Concurrent Medication:

Excluded:

  • Antiretrovirals other than study drugs.
  • Systemic cytotoxic chemotherapy.
  • Foscarnet.

Patients with the following prior conditions are excluded:

  • Chronic diarrhea defined as three or more stools per day for 15 days, within 30 days prior to study entry.
  • Unexplained temperature >= 38.5 C for any 7 days within 30 days prior to study entry.
  • Active participation in other experimental therapy within 30 days prior to study entry.

Prior Medication:

Excluded:

  • Prior nucleoside antiretrovirals of 1 week or longer duration.
  • Any antiretroviral within 90 days prior to study entry.
  • Non-nucleoside reverse transcriptase inhibitors and protease inhibitors within 30 days prior to study entry.
  • Biologic response modifiers such as IL-2 and interferon within 30 days prior to study entry.
Both
12 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States,   Puerto Rico
 
NCT00001067
ACTG 298, 11274
Not Provided
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute of Allergy and Infectious Diseases (NIAID)
Not Provided
Study Chair: Havlir D
Study Chair: Pollard R
Study Chair: Richman D
Study Chair: Friedland G
National Institute of Allergy and Infectious Diseases (NIAID)
May 2012

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP